BioMed Research International / 2020 / Article / Tab 1

Research Article

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma

Table 1

Combination of ribociclib and 5-FU is synergistic in inhibiting the proliferation of some RCC cell lines. Combination studies were performed using the Chou-Talalay method. Briefly, the IC50 of the single drug was determined in the single-arm experiments. Combination studies were performed by treating cells with a single drug alone and an equipotent constant-ratio (according to IC50) combination of two drugs. The combination index (CI) was calculated using the CalcuSyn software. CI of less than 1 indicates synergism, CI equal to 1 indicates additivity, and CI of greater than 1 indicates antagonism of the two drugs in combination.

Combination index (CI)
786-OCaki-2769-PA704ACHNSW839UM-RC-2Caki-1A498

C120
C150
C180

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.